• Facebook
  • X
  • Instagram
MYELOMA360
  • Home
  • MYInsights
  • MYBoard
  • Strategy & Consulting
Select Page

Oncodetect Test Aims to Detect Recurrence Risk Across Solid Tumors

by MM360 Staff | Apr 22, 2025 | Uncategorized

Source: CureToday articles The Oncodetect test detects molecular residual disease across solid tumors using circulating tumor DNA to inform recurrence risk and treatment decisions. Read More

Imfinzi Combination Shows Efficacy in Bladder Cancer Treatment

by MM360 Staff | Apr 22, 2025 | Uncategorized

Source: CureToday articles Dr. Matthew Galsky discusses the FDA approval of Imfinzi and chemo before and after surgery for muscle-invasive bladder cancer, based on the NIAGARA trial. Read More

Aspiring to Make a Difference for Immigrants

by MM360 Staff | Apr 21, 2025 | Uncategorized

Source: CureToday articles “Don’t aspire to make a living. Let’s aspire to make a difference in the Mandarin/Cantonese-speaking community.” Read More

Raising Awareness for Adolescents and Young Adults with Cancer

by MM360 Staff | Apr 21, 2025 | Uncategorized

Source: CureToday articles Carly Stafford Dixon, a rare cancer survivor, highlights the need for AYA cancer awareness to improve support, visibility and access to vital resources. Read More

Clinical Trials Enhance Care for Advanced Gastrointestinal Cancers

by MM360 Staff | Apr 21, 2025 | Uncategorized

Source: CureToday articles Clinical trials improve care and access to novel treatments for advanced gastrointestinal cancers, says Dr. Michael Pishvaian. Read More

Enhertu Combo Improves Progression in HER2+ Metastatic Breast Cancer

by MM360 Staff | Apr 21, 2025 | Uncategorized

Source: CureToday articles Enhertu plus Perjeta demonstrated improvement in progression-free survival versus standard treatment in HER2-positive metastatic breast cancer. Read More
« Older Entries
Next Entries »

Recent Content

  • Immune correlates of anti-BCMA CAR-T products idecabtagene vicleucel and ciltacabtagene autoleucel in a real-world cohort of patients with multiple myeloma
  • The impact of high-risk cytogenetics on treatment efficacy and outcomes of patients with relapsed/refractory multiple myeloma: a systematic review and meta-analysis of randomized controlled trials
  • FDA Approves Linvoseltamab-Gcpt for Treatment of Relapsed or Refractory Multiple Myeloma
  • FDA Grants Accelerated Approval to Lynozyfic for Multiple Myeloma
  • FDA accelerates linvoseltamab-gcpt approval for multiple myeloma
  • Comprehensive machine learning analysis of PANoptosis signatures in multiple myeloma identifies prognostic and immunotherapy biomarkers
  • The impact of high-risk cytogenetics on treatment efficacy and outcomes of patients with relapsed/refractory multiple myeloma: a systematic review and meta-analysis of randomized controlled trials
  • Spatial and single cell mapping of castleman disease reveals key stromal cell types and cytokine pathways
  • Managing IEC-associated enterocolitis following CAR-T therapy in multiple myeloma
  • What Should Patients with Multiple Myeloma Know After ASCO 2025?
  • Facebook
  • X
  • Instagram
©2016-2025 MYELOMA360 & Connect BioMed
We use cookies on our website to give you the most relevant experience by remembering your preferences and repeat visits. By clicking “Accept”, you consent to the use of ALL the cookies.
Do not sell my personal information.
SettingsAccept
Privacy & Cookies Policy

Privacy Overview

This website uses cookies to improve your experience while you navigate through the website. Out of these cookies, the cookies that are categorized as necessary are stored on your browser as they are essential for the working of basic functionalities of the website. We also use third-party cookies that help us analyze and understand how you use this website. These cookies will be stored in your browser only with your consent. You also have the option to opt-out of these cookies. But opting out of some of these cookies may have an effect on your browsing experience.
Necessary
Always Enabled
Necessary cookies are absolutely essential for the website to function properly. This category only includes cookies that ensures basic functionalities and security features of the website. These cookies do not store any personal information.
Non-necessary
Any cookies that may not be particularly necessary for the website to function and is used specifically to collect user personal data via analytics, ads, other embedded contents are termed as non-necessary cookies. It is mandatory to procure user consent prior to running these cookies on your website.
SAVE & ACCEPT